Diabetes mellitus (diabetes) increases coronary heart disease (CHD) morbidity and mortality and is considered a CHD risk equivalent. 1 Diabetes is also a strong risk factor for peripheral vascular disease, including lower extremity peripheral arterial disease (PAD) [2] [3] [4] and carotid artery stenosis (CAS). [4] [5] [6] Risk of PAD and CAS is also higher among patients with prior myocardial infarction or CHD. 3, 6, 7 It is unknown whether diabetes and CHD confer similar risks of vascular disease and whether diabetes is a risk equivalent for peripheral vascular diseases such as PAD or CAS. Moreover, it is unknown whether comorbid diabetes and CHD increase vascular disease risk more than either diabetes or CHD alone. Increased understanding of diabetes as a vascular disease risk equivalent has broad application and importance, as it is estimated that, by 2020, more than 30 million people in the United States will have prevalent diabetes. 8 Using the Life Line vascular screening program of more than 3.5 million participants, 9 this study sought to evaluate whether diabetic participants without CHD have similar odds of both PAD and CAS as nondiabetic participants with established CHD. This study also investigated the odds of PAD and CAS with concomitant diabetes and CHD.
Research design and methods

Study population
The study population has been described previously. 4, 9, 10 The study was based on data provided by Life Line Screening Inc (Independence, OH) to the Society for Vascular Surgery for research purposes. The study cohort consists primarily of self-referred individuals who paid for vascular screening tests out of pocket. Screenings were performed from 2003 to 2008 at more than 20,000 sites nationwide. Before undergoing the screening procedure, individuals completed an extensive questionnaire that included information on demographics, smoking, exercise, cardiovascular risk factors, medical comorbidities, and family history of atherosclerosis and vascular disease. Participants between 30 and 90 years of age were included in this analysis.
Ascertainment of PAD and CAS
Ascertainment of PAD and CAS was determined with simple noninvasive procedures that have high sensitivity and specificity: the ankle brachial index (ABI) and carotid duplex, respectively, 11 as previously described. 9 Systolic blood pressure was measured in both arms (brachial arteries) and both ankles (posterior tibial arteries). If a posterior tibial Doppler signal was inaudible, the dorsalis pedis artery signal was measured. Left and right ABI measurements were obtained by dividing the ankle systolic blood pressure by the highest arm pressure. PAD was defined as an ABI b0.90 in either leg, and participants with an ABI N1.4 were excluded because these values may be falsely elevated due to calcification of the arterial wall. 12 CAS was defined by CAS ≥50% in either (or both) of the internal carotid arteries (internal carotid artery peak systolic velocity ≥ 125 cm/s).
13,14
Definition of diabetes mellitus and other variables of interest
Similar to other studies, 3 diabetes was defined as a self-reported physician diagnosis or the use of glucose-lowering medication. 4, 9 Diabetes severity was defined as (1) diabetes without the use of either oral glucose-lowering agents or insulin, (2) diabetes with oral glucose-lowering agents only, or (3) diabetes with use of insulin with or without use of oral glucose-lowering agents. Coronary heart disease was defined as a self-reported prior myocardial infarction or prior coronary revascularization (coronary artery bypass, angioplasty, or percutaneous coronary intervention). 15 A diagnosis of hypertension was based on either a self-reported diagnosis of hypertension or the use of antihypertensive medications. 15 Hypercholesterolemia was defined as physician diagnosis or medication use. Subjects who had smoked 100 cigarettes during their lifetime and were still currently smoking were considered current smokers. Subjects who had smoked 100 cigarettes during their lifetime and were not currently smoking were considered former smokers. 4 Participants who reported engagement in some kind of vigorous leisure time exercise at least once per week were considered active, and all other participants were considered sedentary. 9 Race and ethnicity were self-reported.
Quality control
As described previously, 9 all Life Line sites use identical protocols and are subject to a quality control program. Included in this program are random monthly audits where ultrasonographic images are graded for each team and individual performance is tracked. Physician audits are performed on a quarterly basis. All results are processed by the results center, and all outliers are reviewed. Percentage of abnormal findings is tracked per team to identify groups finding abnormally high or low number of disease cases. A clinical leadership team holds monthly review meetings to evaluate performance of teams and individual members. For imaging modalities, annual competencies are performed, and all new employees must have demonstrated initial competencies before being allowed to perform testing without supervision.
Statistical analysis
Each individual was assigned a unique identifier, and the investigators had access only to deidentified data. The population of interest was categorized into those with versus those without diabetes and then subgrouped by presence or absence of prior CHD. Baseline characteristics and the prevalence of PAD and CAS between participants with and without diabetes and with and without CHD were compared using the χ 2 test for proportions and a 2-sided independent-sample t test or analysis of variance for continuous variables. Using the population without diabetes or CHD as the referent, odds ratios (ORs) and 95% CIs were calculated by logistic regression to examine the risk of PAD and CAS separately for participants with diabetes alone, CHD alone, or both diabetes and CHD. In addition to unadjusted OR, model 1 was adjusted for age. Model 2 was adjusted for age, race/ ethnicity, body mass index (BMI), hypertension, current smoking, high cholesterol, exercise, and family history. In sex-specific analysis, the strength of association between diabetes, with and without CHD, and PAD and CAS was evaluated using the logistic regression model in model 2. The Wald test was used for testing interaction between the presence of diabetes and CHD for the presence of each vascular disease subtype (PAD and CAS). We also estimated the prevalence and 95% CIs for participants without diabetes or CHD, with diabetes alone, with CHD alone, and with both diabetes and CHD across discrete age groups (40 to 50 years, 51 to 60 years, and so on). Sensitivity analyses were performed across categories of diabetes and CHD. All statistical analyses were performed with PASW (version 18.0; SPSS Inc, Chicago, IL), SAS (version 9.12; SAS Institute Inc, Cary, NC), and the R package (R Development Core Team; available from http://www.r-project.org/).
To estimate the precise relationship between age and different peripheral vascular disease phenotypes, prevalence values from each disease were plotted against age. Prevalence of CAS and PAD was defined as count per 100,000. Prevalence of disease as a function of age was presented using scatter plots. Age was defined on the basis of 6 strata. The first stratum corresponded to participants aged 30 years. All subsequent strata were on the basis of 10-year age increments beginning with 41 years of age. A linear regression model was used to examine age-related trends in CAS and PAD prevalence.
Because prevalence of PAD and CAS had a right-skewed distribution, estimation and inference for PAD and CAS were on the basis of the log scale. Uncertainty associated with the estimated trend was presented using 95% CIs of the regression line.
Results
We analyzed data on 3,522,890 participants participating in the Life Line vascular screening. Overall, 372,330 (10.7%) had diabetes and 182,760 (5.8%) had CHD. Baseline characteristics of the study population stratified by diabetes and CHD are noted in Table I . As expected, participants with both CHD and diabetes were older with more prevalent cardiovascular risk factors.
Peripheral arterial disease and CAS were identified in 4.4% and 3.7% of the population, respectively. The unadjusted prevalence of PAD and CAS is shown in Table II . Compared with participants with no diabetes or CHD, participants with either CHD or diabetes had an increased prevalence of PAD and CAS, respectively (Table II) . The prevalence of PAD and CAS was greatest for men and women with both prior CHD and diabetes. Similar observations were noted across 10-year age groups ( Figure 1 ) and across 10-year age groups stratified by gender (eFigures 1-2). Table III presents age-and multivariable adjusted odds of PAD and CAS for CHD alone, diabetes alone, and diabetes plus CHD. In reference to the no CHD or diabetes group, participants with CHD had a 1.71-fold (Table III) . Further adjustment for race/ethnicity, BMI, hypertension, smoking status, hyperlipidemia, physical activity, and family history somewhat attenuated the odds of PAD and CAS. Figure 2 illustrates the multivariable-adjusted odds of PAD or CAS between participants with CHD alone, diabetes alone, or CHD plus diabetes for these peripheral vascular phenotypes. When analyzed in a multivariable logistic regression model including terms for diabetes, CHD, and diabetes × CHD, there was a significant interaction between diabetes and CHD for risk of PAD (multivariable adjusted P = .04), indicating that comorbid diabetes and CHD act synergistically to increase PAD risk. The interaction term between diabetes and CHD for risk of CAS was nonsignificant (multivariable adjusted P = .25).
To assess the robustness of our findings, the analyses of PAD and CAS risk were repeated across categories of increasing diabetes severity defined as follows: neither oral glucose-lowering agents nor insulin, oral glucose-lowering agents but no insulin, or insulin with or without oral glucose-lowering agents. The multivariable adjusted odds of PAD or CAS with CHD or diabetes alone or as comorbid conditions remained consistent for men and women across categories of increasing diabetes severity (Supplementary Tables I-III) . When insulin use defined diabetes, the association between diabetes and vascular disease subtypes was numerically higher than that for CHD (Supplementary Table III) . When the definition of CHD was restricted to prior myocardial infarction, with or without revascularization, the relationships between diabetes, CHD, and vascular disease subtype were unchanged (data not shown).
Conclusion
The principal finding of the current study is that diabetes mellitus and prevalent CHD significantly increased the odds of different peripheral vascular disease phenotypes compared with participants with no history of CHD or diabetes. Compared with participants with CHD, the odds of PAD and CAS among participants with diabetes were numerically lower (Figure 2) . Although statistically significant, this difference is unlikely to be of clinical significance.
Our findings are consistent with previous studies demonstrating that diabetes and prior CHD are independent risk factors for PAD and CAS. Prospective cohort and cross-sectional studies [16] [17] [18] demonstrated approximately 2-fold increased risk of PAD in diabetic compared with nondiabetic participants, along with a similar risk of PAD (adjusted OR 2.03, 95% CI 1.91-3.46) for participants with versus without prior CHD. 18 Diabetes and prior CHD are also independent risk factors for CAS, although the risk has been less well defined. 6 However, most prior studies of vascular risk from diabetes and prior CHD did not include participants ≥75 years of age and were limited in power. Because diabetes and vascular disease such as PAD and CAS are both strongly associated with age, 9 our study has the advantage of including older participants to examine age-related trends of PAD and CAS associated with diabetes and prior CHD.
Since the Adult Treatment Panel III guidelines, diabetes has been classified as a CHD risk equivalent. 1 Contemporary studies continue to support this classification of the cardiovascular risk associated with diabetes. In a recent analysis of follow-up from ≈1.2 million participants in population cohort studies, diabetic participants without prior myocardial infarction and nondiabetic participants with a prior myocardial infarction experienced a doubling in mortality compared with participants with neither diabetes nor CHD. 19 Although diabetes is considered a CHD risk equivalent, a gradient of CHD risk exists within cohorts of patients with diabetes. 20 Patients with more severe diabetes by increased glycated hemoglobin, 21 diabetes duration, 22 or use of insulin 23 have an increased risk of cardiovascular disease, including PAD, 21 compared with patients with less severe diabetes. In the current study, use or nonuse of glucose-lowering medications or insulin was a proxy for diabetes severity. Participants with diabetes using insulin had the strongest odds of PAD and CAS. However, the association with PAD and CAS was apparent regardless of diabetes definition used. Our results indicate that a gradient of association with peripheral vascular disease may exist for patients with diabetes of increasing severity. Future studies should use well-defined measures of diabetes severity to further refine the association of diabetes with peripheral vascular disease.
We also found that comorbid diabetes and CHD have a particularly high risk for peripheral vascular disease such as PAD and CAS, presumably due to greater baseline comorbidity (Table I) . Prior studies have demonstrated that risk factors such as smoking, hypertension, hypercholesterolemia, and diabetes additively increase the risk of PAD and that PAD risk increases with the presence of each risk factor. 2 Diabetes potentiates the risk of PAD and CAS among participants with prior CHD and confers nearly equivalent risk of PAD among participants without prior CHD.
We observed a difference in the effect of comorbid diabetes and CHD on risk of PAD versus CAS. Together, CHD and diabetes synergistically increased the odds of PAD: participants with both had odds of PAD greater than the product of their individual ORs. In contrast, comorbid diabetes and CHD had a multiplicative (additive on log-OR scale) effect on the odds of CAS. It is unknown whether the difference in interaction for PAD versus CAS is due to lack of statistical power for the smaller group with CAS (most likely) or to underlying differences in disease pathophysiology by vascular disease subtype.
This study may have clinical implications. Our findings indicate that counseling patients with diabetes about peripheral vascular disease prevention and screening may be beneficial, particularly for those patients requiring insulin. Current guidelines recommend the use of resting ABI for patients with suspected PAD, such as individuals 50 years and older with diabetes. 24 Future studies might consider whether prevention and screening for peripheral vascular disease can improve cardiovascular outcomes among patients with diabetes.
Limitations and strengths
There are several limitations to this study. First, this was a cross-sectional, retrospective, observational study design with inherent limitations in study design, analysis, and interpretation. Second, our population database is a self-referred population who paid out of pocket for their screening tests, which may limit the generalizability of our findings. However, as reported previously, the prevalence of cardiovascular disease risk factors in this population database is similar to that reported in the general US population. 9, 25 Moreover, the prevalence of PAD and CAS in the Life Line Survey was similar to other cohorts, 25 demonstrating good external validity for the Life Line Survey population. Third, diabetes and CHD were self-reported and not verified with laboratory testing or in the medical record. However, as we report previously, the prevalence of diabetes in this population database is similar to that reported in other larger cohorts, 4 suggesting that self-reported diabetes status accurately reflects the burden of diabetes in this population database. Nevertheless, we cannot rule out misclassification in which nondiabetic participants mistakenly self-reported having diabetes. It is also possible that some participants had prevalent diabetes that had not yet been diagnosed; similar limitations may exist in regard to self-reported CHD. We also lack information on the duration and percent glycated hemoglobin of participants with diabetes, both of which have been associated with increased cardiovascular disease risk. 22, 26 We therefore may have diluted the actual effect of diabetes on PAD or CAS by including a relatively lower-risk diabetes population. In fact, sensitivity analyses presented in Supplementary Tables I-III demonstrate that the relationship between diabetes and PAD or CAS increased when diabetes was defined separately as oral glucose-lowering medications alone (Supplementary  Table II ) or insulin, with or without oral glucose-lowering medications (Supplementary Table  III) . Both misclassification of prevalent diabetes and a lower-risk diabetes population would have likely biased toward a null result. Fourth, PAD was assessed by ABI using the posterior tibial artery; the dorsalis pedis was used only when the posterior tibial artery was inaudible. Traditionally, the higher of either the dorsalis pedis or the posterior tibial pressures is used for ABI calculations. 12 However, a recent report compared this traditional method with an alternative method using the lower of the 2 ankle artery pressures, and both methods had similar diagnostic and predictive accuracy for all-cause and cardiovascular mortality, suggesting the utility of the alternate method in identifying a clinically meaningful population with PAD. 27 Finally, patients with an ABI N1.4 were excluded because of arterial wall calcification, 12 and the toe brachial index was not available to confirm the presence of PAD in patients with a high ABI, a significant fraction of whom may have diabetes. 24 The present study also has several strengths, including a large number of women and men, the inclusion of a broad age range, and numerically large numbers of participants with different races/ethnicities across the United States. The large number of participants with PAD and CAS allows excellent power and facilitates adjustment for multiple covariates. Standardized assessment of ABIs and duplex carotid artery ultrasonography was performed in every subject, thereby using a simple noninvasive validated procedure for the diagnosis of PAD and CAS that has high sensitivity and specificity.
In a large database of more than 3.5 million self-referred participants, we conclude that diabetes appears to be a CHD risk equivalent for PAD and CAS and that participants with comorbid diabetes and CHD have an especially robust association with PAD and CAS. Our findings suggest that counseling regarding screening and prevention of peripheral vascular disease may be beneficial for patients with diabetes.
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